Growing up in Germany, Melanie Bahlo used to record which birds came and visited her bird feeder in the depths of winter. She was around eight years old at the time and loved discovering new things.
Chemical compounds derived from the cannabis sativa plant, used as an add-on treatment, may help ease symptoms of spasticity in people with motor neuron disease.
A tiny device that electrically stimulates the brain could one day be used to treat conditions such as epilepsy and Parkinson's disease — without open-brain surgery.
MTPConnect's report 'Regenerative Medicine: Opportunities for Australia' provides a roadmap for elevating the sector so it can successfully compete at a global level.
Researchers reviewing studies around the medical use of cannabidiol have found the treatment to be moderately effective in two forms of childhood epilepsy.
A new cellular immunotherapy treatment that targets the Epstein-Barr virus (EBV) has been found to improve multiple sclerosis (MS) symptoms.
Researchers have created a machine learning model, inDelphi, that predicts how human and mouse cells respond to CRISPR-induced breaks in DNA.
Genome editing company LogicBio has partnered with the Children's Medical Research Institute to fast-track gene therapy treatments for children with life-threatening genetic liver disease.
AusCann's hard-shell capsules will target the estimated 1.9 million Australians who suffer chronic neuropathic pain.
Researchers have developed a promising new treatment for chronic wounds, utilising a protein isolated from a surprising source — a parasitic Thai liver fluke.
Biomedical research company BioCurate and pharmaceutical company Novartis have announced they will collaborate on early-stage drug discovery projects.
Biotechnology company Hexima has announced promising results for its plant defensin peptide, HXP124, in fungal nail infections.
Researchers have made a skin graft cell culture using only human cells, which could be used to provide safer treatment for severe burns and other skin conditions in the future.
Two new listings on the Pharmaceutical Benefits Scheme have the potential to extend the lives of Australians with advanced lung cancer and those at risk of a heart attack.
A new investigational antibiotic is proving as effective as the current standard-of-care antibiotic for the treatment of complicated UTIs caused by several multidrug-resistant Gram-negative bacteria.